CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide

Journal of Clinical and Experimental Hematopathology : JCEH
Sakiko TazawaMasafumi Takimoto

Abstract

Plasma cell myeloma (PCM) is a devastating disease with a highly heterogeneous outcome, with survival ranging from a few months to longer than 10 years. Treatment of multiple myeloma has changed markedly in the past decade due to the development of new drugs such as bortezomib, lenalidomide and thalidomide, which have greatly improved the outcome of PCM. The clinical and prognostic value of immunophenotyping in PCM remains questionable. The aim of this study was to determine the diagnostic and prognostic significance of CD200 expression in newly diagnosed PCM. We retrospectively reviewed the records of 107 patients newly diagnosed with PCM at Showa University Hospital between January 2004 and September 2013. Expression of CD200 was studied by immunohistochemistry. Clinical and pathological parameters were compared between CD200-positive and CD200-negative cases. CD200-positive PCM cases had lower serum albumin (p = 0.0001) compared to those without CD200 expression. Our results showed no significant difference in median overall survival between patients with CD200-positive and CD200-negative PCM. However, there was a strong correlation between CD200 expression and serum albumin level. In the CD200-negative group, median overall...Continue Reading

References

May 1, 1995·Cellular Immunology·A LichtensteinJ Berenson
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Feb 14, 2002·British Journal of Haematology·Inger Marie S DahlAnne Husebekk
Jul 25, 2003·British Journal of Haematology·Joth L JacobsonUNKNOWN Southwest Oncology Group
Dec 13, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Brian G M DurieUNKNOWN Scientific Advisors of the International Myeloma Foundation
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Jan 19, 2006·Proceedings of the National Academy of Sciences of the United States of America·John R McWhirterKatherine S Bowdish
Aug 24, 2006·Expert Review of Anticancer Therapy·Paul G RichardsonKenneth C Anderson
Sep 2, 2006·Blood·Jerome MoreauxBernard Klein
Feb 13, 2008·Haematologica·Andy C RawstronUNKNOWN European Myeloma Network
Apr 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gema MateoUNKNOWN GEM Study Group
Sep 9, 2008·Trends in Immunology·Brian T Kawasaki, William L Farrar
Dec 18, 2010·The American Journal of Surgical Pathology·David M Dorfman, Aliakbar Shahsafaei
Feb 1, 2011·British Journal of Haematology·Horatiu OlteanuSteven H Kroft
Dec 20, 2011·American Journal of Clinical Pathology·Daisy AlapatRobert B Lorsbach
May 16, 2012·American Journal of Clinical Pathology·Horatiu OlteanuSteven H Kroft
Aug 18, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·David M DorfmanMiguel A Alonso
Jun 25, 2014·Journal of Clinical Pathology·Jonathan J DoudsShaoying Li

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.